secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neumora Therapeutics, Inc. (NMRA)
CIK:        0001885522
Form:       8-K
Filed at:   2025-05-30T23:59:59+00:00
Accession:  0001193125-25-132307
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud

Neumora Therapeutics stockholders elect directors, approve option repricing and reverse split at 2025 annual meeting
--------------------------------------------------------------------------------

- Elected Alaa Halawa (105,795,914 votes for) and Maykin Ho (114,262,481 votes for) as Class II directors.
- Ratified Ernst & Young as independent auditor for fiscal 2025 with 135,734,870 votes for.
- Approved repricing of certain outstanding stock options under 2020 and 2023 equity plans (101,589,422 for).
- Approved reverse stock split at ratio between 1:5 and 1:30, as determined by board (134,256,461 for).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1885522/000119312525132307/0001193125-25-132307-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1885522/000119312525132307/d908298d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-132307

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer